Sign In
Buy LUMO
$4.34
+0 (+0%)
At Close: Mar 10, 2025
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
10:10am, Tuesday, 04'th Aug 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lumos Pharma
Storied Companies, Compelling Investment Stories: Intellisight® All-Virtual Investor Conference Offers Variety, Depth
12:00am, Tuesday, 04'th Aug 2020
This year’s virtual Intellisight® Investor Conference on Aug. 12 will showcase a variety of companies and compelling investment stories.
Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020
08:01pm, Tuesday, 28'th Jul 2020
AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)
Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...
Lumos Pharma Announces Sale of Priority Review Voucher
08:05pm, Monday, 27'th Jul 2020
AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has ent
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?
12:21pm, Friday, 19'th Jun 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is Lumos Pharma, Inc. (LUMO) A Good Stock To Buy?
07:41pm, Wednesday, 10'th Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
Lumos Pharma Reports First Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
08:01pm, Thursday, 28'th May 2020
- Lumos Pharma expects to initiate its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency (PGHD) prior to the end of 2020 - Additional non-dilutive funds.
Lumos Pharma to Participate in the Jefferies 2020 Healthcare Conference
08:27pm, Wednesday, 27'th May 2020
AUSTIN, Texas, May 27, 2020 -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the.
Lumos Pharma to Report First Quarter 2020 Financial Results and Host a Conference Call on May 28, 2020
02:36pm, Tuesday, 26'th May 2020
Lumos Pharma, Inc. (LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its first quarter 2020 financial results after market cl
Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer
12:00pm, Friday, 24'th Apr 2020
Lumos Pharma, Inc. (LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Aaron Schuchart will be joining the company as Chief Business Officer st
Zacks: InflaRx N.V. (NASDAQ:LUMO) Given Average Rating of "Hold" by Brokerages
10:00am, Sunday, 19'th Apr 2020
InflaRx N.V. (NASDAQ:LUMO) has received an average broker rating score of 3.00 (Hold) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock wi
Jefferies cuts view on Tilray in premarket analyst action
11:05am, Thursday, 16'th Apr 2020
ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with a Buy rating and a $60 (33% upside) price target at Jefferies.eHealth (NASDAQ:EHTH) initiated with an Overweight rating and a $150 (26% upside) pric
The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.
